Exhibit   

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact: Scott Frommer (investors) - +1 336-436-5076 

Investor@labcorp.com

Pattie Kushner (media) - +1 336-436-8263

Media@labcorp.com

Company Information: www.labcorp.com

358 South Main Street

Burlington, NC 27215 

Telephone: (336) 584-5171

LABCORP IS SCHEDULED TO PRESENT AT THE

35TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Burlington, NC, January 5, 2017 - Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 35th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 10, 2017 at 1:30 PM (PT). 

A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. 

About LabCorp® 

Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of $8.5 billion in 2015, LabCorp’s 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

This press release contains forward-looking statements including with respect to estimated 2016 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, adverse actions of governmental and other third-party payers and the results from the Company’s acquisition of Covance. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC, as well as in the risk factors included in Covance’s filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.